Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the market benchmark within the next six months [5][22]. Core Insights - The company has demonstrated impressive performance with a revenue of 3.56 billion yuan in 2024, reflecting a year-on-year growth of 76.3%, and a net profit of 1.43 billion yuan, up 122% year-on-year [2][5]. - The sales expense ratio has improved, decreasing by 5.9 percentage points to 39.7% in 2024, while the net profit margin increased by 8.27 percentage points to 40.2% [2][3]. - The innovative pipeline is progressing steadily, with multiple clinical trials for the drug Vomeletin ongoing, targeting various indications [4][5]. Financial Performance - In Q4 2024, the company achieved a revenue of 1.02 billion yuan, a 52.8% increase year-on-year, and a net profit of 370 million yuan, up 57% year-on-year [2]. - For Q1 2025, the company reported a revenue of 1.1 billion yuan, a 47.9% increase year-on-year, and a net profit of 410 million yuan, reflecting a 34.1% growth [3]. - The projected net profits for 2025, 2026, and 2027 are estimated at 1.7 billion yuan, 2.03 billion yuan, and 2.49 billion yuan, respectively, indicating a strong growth trajectory [5]. Cost Management - The company has effectively optimized its cost structure, with a decrease in the management expense ratio to 4.6% in 2024, down 1.9 percentage points year-on-year [2]. - The research and development expense ratio also saw a decline to 8.8%, down 6.7 percentage points year-on-year, indicating efficient allocation of resources [2]. Market Position and Growth Potential - The company is in a rapid growth phase with Vomeletin's market expansion and the introduction of new products, highlighting its long-term growth potential [5]. - The introduction of the KRASG12C inhibitor, Goretinib, is expected to enhance the company's product offerings and market presence [4][5].

| 证券代码：688578 证券简称：艾力斯 公告编号：2025-011 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 上海艾力斯医药科技股份有限公司 | | | | | | | | | | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 | | | | | | | | | | 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | | | | | | | 重要内容提示： | | | | | | | | | | 本次会议是否有被否决议案：无 | ? | | | | | | | | | 一、 会议召开和出席情况 | | | | | | | | | | （一） 股东大会召开的时间：2025 | | 年 5 | 月 14 | 日 | | | | | | （二） 股东大会召开的地点：上海市浦东新区周浦镇凌霄花路 | | | | | | 268 | 号公司会议 | | | 室 | | | | | | | | | | （三） 出席会议的普通股股东、特别表决权股东、恢复表决 ...

SHANGHAI 68 Yin Chena Road Middle 上海市通力律师事务所关于上海艾力斯医药科技股份有限公司 2024 年年度股东大会的法律意见书 致:上海艾力斯医药科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受上海艾力斯医药科技股份有限公 司(以下简称"公司")的委托,指派本所郭珣律师、俞挺律师(以下简称"本所律师") 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》等 法律法规和规范性文件(以下统称"法律法规")及《上海艾力斯医药科技股份有限公 司章程》(以下简称"公司章程")的规定就公司 2024年年度股东大会(以下简称"本 次股东大会"）相关事宜出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以 了核查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中 的所有签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、 完整和有效的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、出席本次股东大会 人员资格和召集人资格及 ...

证券代码：688578 证券简称：艾力斯 公告编号：2025-011 上海艾力斯医药科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 审议结果：通过 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 14 日 （二） 股东大会召开的地点：上海市浦东新区周浦镇凌霄花路 268 号公司会议 室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 170 | | --- | --- | | 普通股股东人数 | 170 | | 2、出席会议的股东所持有的表决权数量 | 276,877,303 | | 普通股股东所持有表决权数量 | 276,877,303 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 61.5282 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 61.5282 | ...

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown positive returns in recent months and has a diversified portfolio in the healthcare sector [1][3] - As of May 9, 2025, the latest net value of the fund is 2.5040 yuan, with a growth of 0.72%. The fund's return over the past month is 5.17%, ranking 504 out of 783 in its category; over the past three months, the return is 9.06%, ranking 88 out of 778; and year-to-date, the return is 9.87%, ranking 103 out of 773 [1] - The top ten holdings of the fund account for a total of 39.79%, with significant investments in companies such as Heng Rui Pharmaceutical (8.90%), WuXi AppTec (5.12%), and Mindray Medical (2.80%) [1] Group 2 - The fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan. The fund managers are Zhao Bei and Ding Yang [1] - Zhao Bei has extensive experience in the healthcare sector, having served as the fund manager for various healthcare-related funds since 2014, while Ding Yang joined the company in 2017 and currently serves as a fund manager [2]

Core Viewpoint - The article discusses the disparity in employee compensation within the A-share pharmaceutical and biotechnology sector for the year 2024, highlighting the highest and lowest average salaries among companies in the industry. Group 1: Highest Average Salaries - The top ten companies with the highest average employee salaries in the pharmaceutical and biotechnology sector are predominantly innovative drug companies, with BeiGene (百济神州) leading at an average salary of 905,000 yuan [1][2] - The average salary of BeiGene's R&D personnel is 956,000 yuan, with domestic R&D personnel earning an average of 592,000 yuan and overseas R&D personnel earning 1,586,000 yuan [2] - Other companies in the top ten include Dizal Pharmaceutical (迪哲医药) with an average salary of 686,700 yuan and Yihong Pharmaceutical (亚虹医药) with an average salary of 627,400 yuan [2][3] Group 2: Lowest Average Salaries - The ten companies with the lowest average salaries in the sector have an average salary as low as 70,500 yuan, with the lowest being 70,500 yuan at Yisheng Pharmaceutical (益盛药业) [7][9] - The majority of these low-salary companies are traditional Chinese medicine firms and offline pharmacy businesses, with four being Chinese medicine companies [10] - Companies like Teva Pharmaceutical (特一药业) reported a significant decline in net profit, leading to a 10.1% decrease in average salary compared to 2023 [11] Group 3: Salary Trends and Industry Insights - Among the 498 companies in the pharmaceutical and biotechnology sector, 49 companies have an average salary above 300,000 yuan, while 144 companies fall between 200,000 to 300,000 yuan [8] - The article notes that the average salary for most innovative drug companies has increased compared to 2023, with the highest increase being 13.62% for Ailisi (艾力斯) [6] - The article also highlights the challenges faced by offline pharmacies, with a significant drop in customer traffic and profitability due to changes in healthcare policies and increased competition [11][12]

Core Insights - The pharmaceutical and biotechnology sector in A-shares has revealed significant disparities in employee compensation, with innovative drug companies dominating the highest salary rankings [1][2] Group 1: Highest Employee Compensation - The top ten companies in the pharmaceutical and biotechnology sector for employee compensation in 2024 are primarily innovative drug firms, with BeiGene (百济神州) leading at an average salary of 905,000 yuan [1][2] - Other companies in the top ten include Dizhihua Pharmaceutical (迪哲医药) with 686,700 yuan, Yahui Pharmaceutical (亚虹医药) with 627,400 yuan, and others, with salaries ranging from 480,600 yuan to 905,000 yuan [1][2] Group 2: R&D Personnel Impact - Innovative drug companies have a high proportion of R&D personnel, which contributes to elevated overall salary levels; BeiGene employs approximately 11,100 staff, with 3,905 in R&D, making up about 35% of the workforce [2] - The average salary for R&D personnel at BeiGene is 956,000 yuan, with domestic R&D staff earning 592,000 yuan and international R&D staff earning 1,586,000 yuan [2] Group 3: Lowest Employee Compensation - In contrast, the lowest ten companies in the sector have an average salary as low as 70,500 yuan, with a significant representation from traditional Chinese medicine firms [5][6] - The lowest salaries are reported for companies like Yisheng Pharmaceutical (益盛药业) at 70,500 yuan and others, with the majority of these companies experiencing declines in net profit [5][6] Group 4: Performance Trends - Among the top ten companies, eight have seen an increase in average salaries compared to 2023, with the highest increase at 13.62% for Ailisi (艾力斯) [4] - Ailisi's revenue reached 3.558 billion yuan in 2024, marking a 76.29% increase, while net profit rose by 121.97% to 1.43 billion yuan [4] Group 5: Challenges in the Sector - Companies like Te Yi Pharmaceutical (特一药业) have faced significant challenges, with a 91.9% decline in net profit attributed to changes in marketing strategies and reduced sales of key products [6][7] - The retail pharmacy sector is experiencing a downturn, with companies like Yixin Hall (一心堂) and Shuyuan Pingmin (漱玉平民) reporting over 69% declines in net profit due to increased competition and changes in consumer purchasing behavior [7][8]

Investment Rating - The report assigns a "Buy" rating to the company with a target price of 104.5, compared to the last closing price of 87.32 [1]. Core Insights - The company has established a strong presence in the lung cancer treatment sector, with a product matrix gradually taking shape, primarily centered around the drug Vomeletinib [4][5]. - Vomeletinib has rapidly gained market traction after being included in the national medical insurance directory, with projected commercial revenue of 3.5 billion in 2024 and a profit of 1.4 billion [4]. - The company is expanding its product line through collaborations and new drug developments, aiming to enhance its competitive edge in the lung cancer treatment market [5][19]. Summary by Sections Company Overview - The company has evolved into a comprehensive biopharmaceutical enterprise with capabilities in research, production, and sales since its establishment in 2004 [13][14]. - It has developed a full lifecycle drug research system, successfully launching two first-class new drugs [14]. Product Development and Pipeline - Vomeletinib is the only third-generation EGFR-TKI effective against all four types of EGFR mutations, with ongoing clinical trials for various indications [5][19]. - The company is collaborating with ArriVent to expand Vomeletinib's international market presence, which will further enhance its revenue potential [5][21]. - The introduction of new drugs like KRAS inhibitors and SHP2 inhibitors is expected to complement Vomeletinib and address treatment resistance issues [19][64]. Financial Projections - The company anticipates significant revenue growth, with projected sales of 3.56 billion in 2024, increasing to 7.45 billion by 2027, reflecting a compound annual growth rate of over 100% for Vomeletinib [8][41]. - The net profit is expected to rise from 1.43 billion in 2024 to 2.89 billion in 2027, indicating strong profitability growth [8]. Market Potential - The EGFR-TKI market in China is projected to grow significantly, with a compound annual growth rate of 34.8% from 2017 to 2022, reaching 205 billion by 2027 [46][49]. - The company is well-positioned to capture market share in the rapidly expanding lung cancer treatment sector, particularly with the increasing prevalence of EGFR mutations among patients [45][57].

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown positive growth in recent months and has a diversified portfolio in the healthcare sector [1][3]. - As of April 30, 2025, the latest net value of the fund is 2.5180 yuan, reflecting a growth of 1.82%. The fund's return over the past month is 2.07%, ranking 41 out of 469 in its category. Over the past three months, the return is 11.71%, ranking 45 out of 467, and since the beginning of the year, the return is 10.49%, ranking 44 out of 465 [1]. - The fund's total assets amount to 2.724 billion yuan as of March 31, 2025, and it was established on November 18, 2014. The fund managers are Zhao Bei and Ding Yang [1]. Group 2 - The top ten holdings of the fund account for a total of 39.79%, with significant investments in companies such as Heng Rui Pharmaceutical (8.90%), WuXi AppTec (5.12%), and Aier Eye Hospital (4.94%) [1]. - Zhao Bei, the fund manager, has extensive experience in the healthcare sector, having been with ICBC Credit Suisse Asset Management since 2010 and managing the healthcare fund since its inception in 2014. Ding Yang, the co-manager, has a strong academic background and joined the firm in 2017 [2].

上海艾力斯医药科技股份有限公司 2024 年年度股东大会会议资料 二零二五年五月 目 录 | 2024 | 年年度股东大会会议须知 - 2 - | | --- | --- | | 2024 | 年年度股东大会会议议程 - 4 - | | 2024 | 年年度股东大会会议议案 - 5 - | | 议案一：关于公司《2024 | 年年度报告》及其摘要的议案 - 5 - | | 议案二：关于公司《2024 | 年度董事会工作报告》的议案 - 6 - | | 附件一：上海艾力斯医药科技股份有限公司 | 2024 年度董事会工作报告 - 7 - | | 议案三：关于公司《2024 | 年度监事会工作报告》的议案 - 12 - | | 附件二：上海艾力斯医药科技股份有限公司 | 年度监事会工作报告 - 2024 13 - | | 议案四：关于公司《2024 | 年度财务决算报告》的议案 - 16 - | | 附件三：上海艾力斯医药科技股份有限公司 | 2024 年度财务决算报告 - 17 - | | 议案五：关于公司《2024 | 年度独立董事述职报告》的议案 - 24 - | | 附件四：上海艾力斯医药科技股份有限公司 ...